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Summary
All blood cell lineages derive from a common hemato-
poietic stem cell (HSC). The current model implicates
that the first lineage commitment step of adult pluri-
potent HSCs results in a strict separation into com-
mon lymphoid and common myeloid precursors. We
present evidence for a population of cells which, al-
though sustaining a high proliferative and combined
lympho-myeloid differentiation potential, have lost
the ability to adopt erythroid and megakaryocyte lin-
eage fates. Cells in the Lin−Sca-1+c-kit+ HSC compart-
ment coexpressing high levels of the tyrosine kinase
receptor Flt3 sustain granulocyte, monocyte, and B
and T cell potentials but in contrast to Lin−Sca-1+c-
kit+Flt3− HSCs fail to produce significant erythroid
and megakaryocytic progeny. This distinct lineage re-
striction site is accompanied by downregulation of
genes for regulators of erythroid and megakaryocyte
development. In agreement with representing a lym-
phoid primed progenitor, Lin−Sca-1+c-kit+CD34+Flt3+
cells display upregulated IL-7 receptor gene expres-
sion. Based on these observations, we propose a re-
vised road map for adult blood lineage development.
Introduction
All blood cell lineages derive from a common hemato-
poietic stem cell (HSC) responsible for life-long and bal-
anced blood cell production, in man amounting to mil-
lions of cells per second in steady state (Ogawa, 1993).
Although molecular pathways (cytokine receptors and
transcription factors) regulating the development of the
different blood cell lineages have been identified (Met-
calf, 1993; Shivdasani and Orkin, 1996; Zhu and Emer-
son, 2002), the role of these and other pathways in
governing hematopoietic lineage commitment remains
elusive.
Developments in state of the art technologies ena-
bling identification and prospective purification of HSCs
and downstream progenitor cells at different stages of
commitment (Akashi et al., 2000; Kondo et al., 1997;
Matsuzaki et al., 2004; Osawa et al., 1996) have and will*Correspondence: sten.jacobsen@med.lu.secontinue to play a key role in identifying the molecular
mechanisms governing HSC self-renewal as well as lin-
eage fate determination. The identification of common
myeloid and lymphoid progenitors (CMPs and CLPs,
respectively; Akashi et al., 2000; Kondo et al., 1997)
lends support to the classical and currently prevailing
model for hematopoietic commitment and blood lin-
eage development, implicating that the first and deci-
sive lineage commitment step of adult HSCs results in
an immediate and complete separation of myelopoiesis
and lymphopoiesis (Reya et al., 2001). Importantly, this
model proposes that short-term HSCs (ST-HSCs) and
multipotent progenitors (MPPs), although having re-
duced self-renewal capacity, sustain the full lympho-
myeloid lineage potentials of long-term HSCs (LT-
HSCs) (Reya et al., 2001).
Virtually all LT-HSC, ST-HSC, and MPP activities in
adult mouse bone marrow (BM) have been shown to
reside in the small Lin−Sca-1+c-kithi (LSK) HSC com-
partment (0.1% of all BM cells; Ikuta and Weissman,
1992; Li and Johnson, 1995; Spangrude et al., 1988;
Weissman et al., 2001). Within the adult LSK compart-
ment, LT-HSCs have been demonstrated to lack ex-
pression of CD34 as well as the cytokine tyrosine ki-
nase receptor Flt3 (Adolfsson et al., 2001; Christensen
and Weissman, 2001; Osawa et al., 1996), whereas ST-
HSCs are LSKCD34+Flt3− (Osawa et al., 1996; Yang et
al., 2005). The LSKCD34+Flt3− ST-HSC population gives
rise to a third population of LSK cells, all coexpressing
Flt3 and CD34 and representing as much as 50% of the
LSK HSC compartment (Adolfsson et al., 2001). Upon
transplantation LSKCD34+Flt3+ (hereafter called LSK
Flt3+) cells give primarily rise to rapid and robust lym-
phoid reconstitution (Adolfsson et al., 2001). A role for
Flt3 in early lymphoid development has been further
substantiated in studies of mice deficient in expression
of Flt3 or its ligand, as these mice have reductions in
early B and T cell progenitors as well as the CLPs
(Mackarehtschian et al., 1995; McKenna et al., 2000;
Sitnicka et al., 2002). Furthermore and in line with the
documented synergistic interaction between Flt3 li-
gand (FL) and IL-7 on uncommitted progenitors (Veiby
et al., 1996), mice double deficient in FL and interleu-
kin-7 receptor α (IL-7Rα) expression lack mature B cells
and evidence for B cell commitment in fetal as well as
adult hematopoiesis (Sitnicka et al., 2003).
Although having a lymphoid-dominated short-term
reconstitution potential, LSK Flt3+ cells possess, at the
single-cell level, a combined myeloid (granulocyte-
monocyte; GM) and lymphoid (B and T cell) differentia-
tion potential (Adolfsson et al., 2001) and should, there-
fore, according to the current model for HSC lineage
commitment (Reya et al., 2001), also possess a mega-
karyocyte (Mk) and erythroid (E) differentiation poten-
tial. However, in contrast to LSKCD34+Flt3− ST-HSCs
and megakaryocyte/erythroid progenitors (MkEPs), LSK
Flt3+ cells lack in vivo day 8 clonogenic colony-forming
unit spleen (CFU-Sd8) activity (Yang et al., 2005), typical
for reconstituting cells capable of rapidly reconstituting
myelo-erythropoiesis following lethal irradiation (Akashi
Cell
296et al., 2000; Na Nakorn et al., 2002; Osawa et al., 1996; W
lTill and McCulloch, 1961).
aSince the CD45 (common leukocyte antigen) con-
cgenic mouse model typically used to assess HSC re-
gconstitution and lineage potentials (Bryder and Jacob-
osen, 2000) prevents direct evaluation of Mk and E
alineage potentials (as platelets and erythrocytes do not
aexpress CD45), we here applied a number of compli-
dmentary in vitro and in vivo approaches to directly eval-
muate the Mk and E potentials of LSK Flt3+ cells. Herein,
bwe provide compelling evidence for a novel route for
Fearly blood lineage commitment and development, in
Bthat LSK Flt3+ cells, although sustaining a high prolifer-
ative and combined lympho-myeloid differentiation po-
stential, have lost the ability to significantly adapt Mk
Hand E lineage fates and in agreement with this down-
aregulate expression of a number of genes critically in-
lvolved in development of these lineages.
R
cResults
a
SSingle LSK Flt3+ Lympho-Myeloid Stem/Progenitor
tCells Lack Significant In Vitro Megakaryocyte
cand Erythroid Differentiation Potentials
(We recently demonstrated that LSK Flt3+ BM cells,
talthough predominantly and efficiently reconstituting
Llymphopoiesis in vivo, have a combined B, T, and my-
peloid differentiation potential (Adolfsson et al., 2001).
2Specifically, using clonal assays, 95% of single LSK
LFlt3+ cells possessed an M, 85% G, and 45% a com-
cbined B and T cell potential, demonstrating that a large
pfraction of LSK Flt3+ cells have a combined macro-
1phage, granulocyte, B, and T cell potential (Adolfsson
uet al., 2001). Here, to directly confirm their lympho-
(myeloid potential, highly purified (>97%) LSK Flt3+ cells
F
(25% highest Flt3 expressing LSK cells; Figure 1A; Ad-
(
olfsson et al., 2001) were investigated at the single cell
w
level for their combined B cell and GM potential. As
o
much as 67% of all single LSK Flt3+ cells demonstrated e
sufficient clonal growth to be evaluated in this assay, a
of which 70% revealed a combined B and GM potential L
(Figure 1B). i
We also investigated the B cell potential of LSK Flt3+ n
cells on the OP9 cell line that efficiently supports B cell L
development (Vieira and Cumano, 2004). When cultured a
on OP9 for 14–28 days, all single LSK Flt3+-derived 1
clones (40% cloning efficiency) produced B220+CD19+ B f
cells (Figure 1C). w
The recent development of the OP9 cell line express-
ing the notch ligand delta like1 (OP9-DL1) has dramati- l
cally enhanced the efficiency by which cells with T cell 2
potential can be detected from uncommitted progeni- i
tors in vitro (Schmitt and Zuniga-Pflucker, 2002; Vieira F
and Cumano, 2004). When cultured on OP9-DL1, as e
much as 91% of LSK Flt3+ single cell-derived clones g
(50% cloning efficiency) contained CD3-, CD4-, and t
CD8α-expressing cells (Figure 1C). Noteworthy, in m
clones investigated, we concomitantly to T cell devel- c
opment frequently also observed production of Mac-1+ c
myeloid cells (data not shown). In further support of t
their T cell potential, we also investigated by PCR the r
single LSKflt3+-derived clones on OP9-DL1 for expres- e
5sion of the early T cell-restricted genes CD3e and LcK.hereas uncultured LSK Flt3+ cells and OP9-DL1 cells
acked detectable expression of these genes, as much
s 15 out of 16 (94%) investigated single LSK Flt3+
lones derived on OP9-DL1 expressed both of these
enes (Figure 1D), demonstrating efficient commitment
f LSK Flt3+ cells along the T-lineage pathway. We also
nalyzed the recombination status at the TCRb locus
nd found that 11 out of 12 (92%) analyzed LSK Flt3+-
erived clones showed DJ rearrangements. These were
ainly D2-Jβ2.1 but other recombination events could
e detected as well (Figure 1E). Thus, a majority of LSK
lt3+ cells possess a combined granulocyte, monocyte,
, and T cell potentials.
The current model for hematopoietic development
uggests that the first lineage commitment step of
SCs leads to a strict separation of myelopoiesis (GM
nd megakaryocyte/erythroid; Mk and E lineages) and
ymphopoiesis (Akashi et al., 2000; Kondo et al., 1997;
eya et al., 2001). According to this model, LSK Flt3+
ells having a combined B, T, and GM potential should
lso possess a Mk and E developmental potential.
ince the Mk and E lineages upon differentiation cease
o express the pan-hematopoietic marker CD45, typi-
ally used to track all other blood cell lineages in vivo
Bryder and Jacobsen, 2000), we here first compared
he in vitro Mk potential of highly purified LSK Flt3+ and
SK Flt3− cells containing LSKCD34−Flt3− LT-HSCs but
redominantly LSKCD34+Flt3− ST-HSCs (Yang et al.,
005). Strikingly, whereas as much as 57% of single
SK Flt3− cells produced Mk in response to a cytokine
ombination that included thrombopoietin (TPO), the
rimary regulator of Mk production (Gurney et al.,
994), only 2% of purified LSK Flt3+ cells produced Mk
nder the same conditions (KL + FL + TPO + IL-3; KFT3)
Figure 2A). Furthermore, whereas almost 40% of LSK
lt3− cells produced Mk also in the absence of TPO
KL + IL-3 + EPO + IL-11; K3E11), no Mk development
as observed from LSK Flt3+ cells (Figure 2A). Testing
f other cytokine combinations and culture conditions
fficiently promoting Mk development of LSK Flt3− cells
lso failed to promote significant Mk development from
SK Flt3+ cells (J.A. and S.E.J., unpublished data). The
nability of LSK Flt3+ cells to generate Mk in vitro was
ot due to different lineage differentiation kinetics of
SK Flt3+ and LSK Flt3− cells, as single LSK Flt3− cells
t high frequencies efficiently produced Mk by 8 and
0 days (Figure 2B) as well as 12–15 days (Figure 2A)
ollowing initiation of culture, whereas few or no Mk
ere observed at any time point from LSK Flt3+ cells.
The Mk and E lineages are developmentally closely
inked and share a common progenitor (Akashi et al.,
000). Thus, experiments were next designed to also
nvestigate the erythroid differentiation potential of LSK
lt3+ cells in vitro. To pursue this, we developed a new
fficient and highly specific assay for directly investi-
ating the erythroid potential of uncommitted progeni-
or/stem cells at the single cell level (see the Experi-
ental Procedures). Single LSK Flt3− and LSK Flt3+
ells were cultured under conditions and in a cytokine
ombination (KFT3E) efficiently supporting myelo-ery-
hroid development, and after 14–15 days, clonally de-
ived cells were investigated by FACS for generation of
rythroid (TER119+Gr-1/Mac-1−) progeny. As much as
3% of single LSK Flt3− cells generated TER119+Gr-1/
Flt3+ Lineage-Restricted Lymphomyeloid Stem Cells
297Figure 1. Combined Lympho-Myeloid Differentiation Potential of LSK Flt3+ Cells
(A) Sca-1+ BM cells expressing high levels of c-kit (left) were sorted into Lin−Flt3+ (with highest 25% Flt3 expression) and Lin−Flt3− populations
as indicated (right).
(B) Frequencies of clonal single LSK Flt3+ cells demonstrating combined GM and B cell, B cell only, and GM potential only. Mean (SD) values
of two experiments.
(C) B and T cell potential of single LSK Flt3+ cells evaluated after 14–28 days of culture on OP9 and OP9-DL1 stroma cells, respectively. Mean
(SD) results from FACS analysis of a total of 34 clones on OP9 (from two experiments) and 104 clones grown on OP9-DL1 (from four
experiments). Clones were picked at day 14–28 and analyzed by FACS. Clones, grown on OP9 stroma, which contained cells expressing both
B220 and CD19 were considered to have B cell potential, and clones grown on OP9-DL1 stroma, if containing CD3-, CD4-, and CD8α-
expressing cells were considered to have T cell potential. As much as 40% and 50% of LSK Flt3+ cells grown on OP9 and OP9-DL1,
respectively, formed large enough clones to be analyzed.
(D) Ethidium bromide-stained agarose gel with PCR products of ACTIN, LcK, and CD3e message from 1000 OP9-DL1 cells, 1000 uncultured
LSK Flt3+ cells, thymocytes, or one twentieth of three representative (out of 16 analyzed) LSK Flt3+ single-cell clones derived on OP9-DL1.
(E) Autoradiogram of TCRb D-J2 rearrangements in WEHI-3 (myelomonocytic) cells, sorted CD3+ spleen cells, uncultured LSK Flt3+ cells,
OP9-DL1 cells, and three representative (out of 12 analyzed) LSK Flt3+ clones derived on OP9-DL1.Mac-1− erythroid progeny (Figures 2C and 2D). In con-
trast, whereas LSK Flt3+ cells efficiently generated my-
eloid (GM; Gr-1/Mac-1+TER119−) progeny, only 3% (one
out of 34 cells investigated) produced erythroid prog-
eny (Figures 2C and 2D). Thus, purified LSK Flt3+ cells
lack (beyond the frequency of contaminating LSK Flt3−
cells; 1%–3%; Experimental Procedures) signficant in vi-
tro Mk and E differentiation potential.
LSK Flt3+ Lympho-Myeloid Stem/Progenitor Cells
Lack Significant In Vivo Megakaryocyte
and Erythroid Developmental Potential
The inability of most LSK Flt3+ cells to produce mega-
karyocytic and erythroid progeny in vitro could poten-
tially be due to the utilized conditions not providing the
optimal/unique signals required for Mk and E develop-
ment from this stem/progenitor cell population. Thus,
we next designed in vivo experiments to further investi-
gate the Mk and E potentials of LSK Flt3+ cells. Since
Mk progenitors, but not platelets or mature Mk, express
the panhematopoietic marker CD45, we used the CD45
congenic mouse model (Bryder and Jacobsen, 2000) to
compare the ability of transplanted LSKCD34+Flt3− ST-
HSCs and LSK Flt3+ cells to generate Mk progenitors
(CFU-Mk) following lethal myeloablation (Figure 3A).Importantly, complete myeloablation results in severe/
lethal thrombocytopenia (Kempf et al., 1980; Uchida et
al., 1998), thereby activating pathways promoting Mk
development. One week following transplantation of
10,000 LSKCD34+Flt3− or LSK Flt3+ cells (CD45.1)
in competition with 200,000 unfractionated BM cells
(CD45.2), the spleens (and BMs; data not shown) of re-
cipient mice (CD45.2) were highly and comparably re-
constituted by (CD45.1+) LSK Flt3+ (mean reconstitution
77%) and LSKCD34+Flt3− (mean reconstitution 75%)
cells. However, whereas more than 80 Mk progenitors
were generated per transplanted LSKCD34+Flt3− cell at
this time, Mk progenitors were almost undetectable
among the cells derived from reconstituting LSK Flt3+
cells (Figure 3B), and mice transplanted with low num-
bers of LSKCD34+Flt3− cells, corresponding to the con-
tamination within sorted LSK Flt3+ cells (1%–3% as
determined by reanalysis), demonstrated that the very
low numbers of Mk progenitors generated from purified
LSK Flt3+ cells could be derived from contaminating
LSKCD34+Flt3− cells (J.A. and S.E.J., unpublished
data). In contrast, LSK Flt3+ cells produced GM progen-
itors following transplantation (>100 per transplanted
cell), although less than LSK Flt3− cells (Figure 3C).
Experiments were next designed to also investigate
Cell
298Figure 2. Lack of In Vitro Megakaryocyte and Erythroid Potential of LSK Flt3+ Cells
(A) Single LSK Flt3+ and LSK Flt3− cells were cultured for 12–15 days in the presence of the indicated cytokine combinations (Experimental
Procedures). Bars show frequencies of LSK Flt3+ and LSK Flt3− cells forming colonies (open bars) and Mks (filled bars). Results represent
mean (SEM) values from 3–11 experiments.
(B) Clonal and Mk potential of single LSK Flt3+ and LSK Flt3− cells cultured in KFT3 for 8 and 10 days. Mean (SD) values of two experiments.
* p < 0.05, LSK Flt3+ versus LSK Flt3− cells. 0 = no Mk formed.
(C) Representative profiles of TER119 and GR-1/Mac-1 expression on progeny of single LSK Flt3− (left) and LSK Flt3+ (right) cells cultured for
14 days in the presence of KFT3E.
(D) Frequencies of single LSK Flt3− and LSK Flt3+ cells producing erythroid (TER119+Gr-1/Mac-1−) progeny in vitro. Results represent mean
(SD) values from 2 experiments, with a total of 30 and 34 clones, investigated for LSK Flt3− and LSK Flt3+ cells, respectively.the erythroid differentiation potential of LSK Flt3+ cells s
uin vivo, again taking advantage of lethally irradiated
mice developing severe cytopenia and providing an en- i
Fvironment permissive for E development. However, lt3 and LSKCD34 Flt3 cells (Figures 4A and 4B). Two
Figure 3. In Vivo Megakaryocyte and Granu-
locyte/Macrophage Potential of LSK Flt3+
Cells
(A) Experimental design. Lethally irradiated
(CD45.2) mice were transplanted with FACS-
sorted LSK Flt3+ or LSKCD34+Flt3− (CD45.1)
cells and congeneic (CD45.2) BM support
cells. CD45.1+ cells were sorted from spleen
and BM 7–9 days posttransplantation and
cultured in methylcellulose for an additional
8–12 days and scored for Mk (B) and GM
(C) progenitors (CFU-Mk and CFU-GM,
respectively). Mean (SEM) values of four ex-
periments. * CFU-Mk p < 0.05, LSK Flt3+
versus LSKCD34+Flt3− cells. The difference
in CFU-GM formation of LSK Flt3+ and
LSKCD34+Flt3− cells did not reach statistical
significance (p = 0.11).ince mature erythrocytes lack expression of CD45, we
tilized congenic mice expressing different hemoglobin
soforms as donors (Hbbs) and recipients (Hbbd) of LSK
+ + −
Flt3+ Lineage-Restricted Lymphomyeloid Stem Cells
299Figure 4. Myeloid Potentials of LSK Flt3+ Cells and CMPs
(A) Lethally irradiated (CD45.2, Hbbd) mice were transplanted with 200 purified LSK Flt3+ or LSKCD34+Flt3− (CD45.1, Hbbs) cells and 200,000
congeneic (CD45.2, Hbbd) support BM cells. PB samples were analyzed at 3 and 4 weeks posttransplantation for recipient (Hbbd) and donor
(Hbbs) hemoglobin reconstitution by electrophoresis. One representative example of electrophoresis gel with PB from two mice transplanted
with 200 LSKCD34+Flt3− cells, three mice transplanted with 200 LSK Flt3+ cells, and three PB samples from nontransplanted mice of donor
(Hbbs) and recipient (Hbbd) types.
(B) Mean (SD) values from two experiments with 12–13 mice in each group and time point. Numbers above bars show frequency of trans-
planted mice positive for donor-derived (Hbbs) erythroid reconstitution. * p < 0.05, LSK Flt3+ versus LSKCD34+Flt3− cells.
(C) In vitro B cell (B220+CD19+) and T cell (CD4+CD8+) potential of single LSK CD34+Flt3+ cells and 10 Flt3− CMPs evaluated at 21–28 days
of culture on OP9 and OP9-DL1 cell lines, respectively. Results are presented as mean (SD) percentages of single cells with B and T cell
potential from three to five experiments. A total of 180 (OP9) and 300 (OP9-DL1) single LSK Flt3+ cells and 1440 (OP9) and 1440 (OP9-DL1)
CMPs were investigated.
(D and E) Combined in vitro MkE and GM potential of single LSK Flt3− cells (D) and Flt3− CMPs (E). In each experiment, 360 to 600 single
CMPs and LSK Flt3− cells were plated into conditions promoting both MkE and GM development. Results show mean percentages (SD) of
analyzed clones containing GM or MkE lineages alone or in combination (Mix), from eight LSK Flt3− and five Flt3− CMPs experiments.hundred LSK Flt3+ or LSKCD34+Flt3− (Hbbs) cells were
transplanted in competition with 200,000 BM cells
(Hbbd) into lethally irradiated recipients (Hbbd). Three
and four weeks posttransplantation, LSKCD34+Flt3−
cells contributed substantially to E reconstitution in all
(13/13) mice by as much as 18% and 16%, respectively,
whereas only one of thirteen mice showed detectable
E reconstitution from transplanted LSK Flt3+ cells (Fig-
ures 4A and 4B), although the contribution to other
blood lineages (B, T, and myeloid cells) was as much
as 14% ± 5% and comparable to that of LSKCD34+Flt3−
cells (22% ± 14%). Thus, in contrast to LSKCD34+Flt3−
cells, most LSK Flt3+ cells lack in vitro as well as in vivo
Mk and E development potential.
Our finding that LSK Flt3+ cells sustain B, T, M, and
G potential but lack significant Mk and E potential
could be compatible with CMPs’ (Akashi et al., 2000;
Miyamoto et al., 2002) predominantly being derived
from LSK Flt3− (or potentially LSK Flt3low) cells that also
have Mk and E potential. Thus, we next compared the
combined GM and MkE potentials of single LSK Flt3−
cells and CMPs. As recent studies had demonstrated
that only the Flt3− fraction of CMPs is myeloid re-
stricted (D'Amico and Wu, 2003), we purified Flt3−CMPs (Lin−IL-7Rα−Sca-1−c-kit+CD34+FcR−Flt3−; seeFigure S1 in the Supplemental Data available with this
article online). Importantly, no analyzed Flt3− CMPs
generated B or T cells on OP9 (1440 cells total; n = 3)
and OP9-DL1 (1440 cells total; n = 3), respectively (Fig-
ure 4C). Using culture conditions promoting both MkE
and GM differentiation (Experimental Procedures and
Figure 4), as much as 83% (n = 8) and 60% (n = 5) of
single LSK Flt3− cells and Flt3− CMPs formed clones,
respectively. Noteworthy, whereas 56% of analyzed
LSK Flt3− clones had a mixed MkE and GM composi-
tion (Figure 4D), pure GM (59%) and MkE (33%) colo-
nies dominated among Flt3− CMP clones analyzed, al-
though 8% of Flt3− CMPs revealed a combined MkE
and GM potential (Figure 4E). Another striking observa-
tion was that as much as 40% (n = 5) of all Flt3− CMP-
derived clones represented small colonies (too small
for cytospin analysis) composed exclusively of large
megakaryocytes.
Downregulation of the Expression of Genes for
Nonredundant Regulators of Megakaryocyte and
Erythroid Development in LSK Flt3+ Cells
A number of cytokine receptors and transcription
factors have been demonstrated to be critically in-
volved in Mk and E development (Cantor and Orkin,
Cell
3002002; Shivdasani and Orkin, 1996; Zhu and Emerson,
a2002). In particular, Mk as well as E development are
strictly dependent on the transcription factors GATA-1 F
sand SCL/TAL-1 (Mikkola et al., 2003; Orkin et al., 1998;
Shivdasani and Orkin, 1996). Importantly, the expres- m
lsion of these genes has not only been reported in
E- and Mk-committed progenitors, but also in multipo- s
Gtent lympho-myeloid HSC populations with E and Mk
potential, as has expression of the genes for the nonre- t
edundant hematopoietin receptors for Epo and Tpo
(EpoR and TpoR, respectively) (Akashi et al., 2000; Mi- n
cyamoto et al., 2000; Terskikh et al., 2003). Thus, any
multipotent stem/progenitor cell population downstream G
of HSCs with E and Mk potential would be expected to
express these genes. Using quantitative RT-PCR, we F
pfound in agreement with their sustained GM potential
that LSK Flt3+ as LSKCD34+Flt3− ST-HSCs expressed o
ihigh levels of mRNA for the transcription factor PU.1
as well as the G-CSFR (Figures 5B and 5C). However, t
lin support of their loss of E and Mk developmental
potential, LSK Flt3+ cells, in contrast to LSKCD34+Flt3− d
cells, revealed no detectable gene expression of
GATA-1 and EpoR (Figures 5D and 5E) and had reduced D
expression of SCL/TAL-1, NF-E2, and TpoR (Figures
5F–5H). Most noteworthy, whereas LSKCD34+Flt3− ST- I
fHSCs as expected expressed little or no mRNA for
IL-7Ra, the expression was clearly upregulated in LSK aFigure 5. Downregulation of Essential Erythroid and Megakaryocyte Transcription Factors and Cytokine Receptor Genes and Upregulation of
IL-7Ra mRNA Expression in LSK Flt3+ Cells
Quantitative PCR data of indicated genes in FACS-sorted LSKCD34+Flt3− and LSK Flt3+ cells. Lin−c-kit+ BM cells (containing committed
progenitor cells of Mk, E, GM, and B lineages), and B220+ spleen cells (mature B cells) were used as controls for the PCR analysis, with the
expression levels in Lin−c-kit+ cells set to 1. All data were normalized to the expression of HPRT. Results represent mean (SEM) values from
at least two independent experiments, with PCR analysis in each experiment performed in triplicates. ND = no detectable expression after
45 cycles of PCR.Flt3+ cells (Figure 5I).We also performed a multiplex single-cell RT-PCR
nalysis (Hu et al., 1997) to investigate whether LSK
lt3+ cells that had turned on IL-7Rα expression might
till represent multipotent progenitors with sustained
yeloid potential and gene expression or rather more
ymphoid-restricted progenitors. Whereas a majority of
ingle LSKCD34+Flt3− cells were found to express
-CSFR mRNA, none were IL-7Ra+ (Figure 6A). In con-
rast, 9% of single LSK Flt3+ cells were found to
xpress detectable IL-7Ra mRNA (Figure 6B), and,
oteworthy, the vast majority of these continued to
oexpress the gene for the nonredundant myeloid
-CSFR (Figures 6B and 6C).
Thus, in contrast to upstream pluripotent LSKCD34+
lt3− ST-HSCs and downstream committed E and Mk
rogenitors, LSK Flt3+ cells downregulate expression
f transcription factors and cytokine receptors critically
nvolved in development of the E and Mk lineages, sus-
ain expression of GM-associated genes, and upregu-
ate expression of the IL-7Ra, required for B and T cell
evelopment (Peschon et al., 1994).
iscussion
n the present studies, we provide compelling evidence
or the existence in adult hematopoiesis of a prominent
nd potent lympho-myeloid stem/progenitor cell pop-ulation within the LSK HSC compartment, which lacks
Flt3+ Lineage-Restricted Lymphomyeloid Stem Cells
301Figure 6. Multiplex Single-Cell RT-PCR De-
monstrates Coexpression of G-CSFR and IL-
7Rα in LSK Flt3+ Cells
Representative gel analysis data for expres-
sion of HPRT, CD34, c-kit, G-CSFR, and IL-
7Ra in single LSKCD34+Flt3− cells (A) and
LSK Flt3+ cells (B).
(C) Frequency (SD) of G-CSFR coexpression
on IL-7Ra-expressing LSK Flt3+ cells. Only
cells in which expression of CD34 and c-kit
as well as the housekeeping gene HPRT
were detected were included for further
analysis of IL-7Ra and G-CSFR expression.
Mean (SD) values from two independent ex-
periments, representing a total of three and
two 96-well plates analyzed for LSKCD34+
Flt3+ and LSKCD34+Flt3− cells, respectively.
M = marker.significant Mk and E developmental potential, contrary
to what would be predicted from the classical and pre-
vailing model for hematopoietic lineage commitment in
adult hematopoiesis (Akashi et al., 2000; Kondo et al.,
1997; Reya et al., 2001). That LSK(CD34+)Flt3+ cells
(25% highest Flt3-expressing LSK cells), although sus-
taining a combined myeloid and lymphoid potential at
the single cell level, have already undergone a first step
of HSC lineage restriction through loss of Mk and E
potential was substantiated by several lines of experi-
mental evidence. First, in vitro and in vivo biological
assays efficiently promoting Mk and E development
from LSKCD34+Flt3− HSCs, including myeloablative
conditioning activating endogenous pathways for Mk
and E production, failed to promote significant devel-
opment of these lineages from LSK Flt3+ cells beyond
what could be expected from sorting impurities (1%–
3%). Furthermore, in contrast to the LSKCD34+Flt3− ST-
HSCs, LSK Flt3+ cells lacked detectable mRNA expres-
sion for GATA-1 and EpoR and downregulated gene
expression for SCL/TAL1, NF-E2, and TpoR. This com-
bined with the fact that not only committed MkEPs
(Akashi et al., 2000; Miyamoto et al., 2002) but also up-
stream HSCs (in agreement with previous studies; Mi-
yamoto et al., 2002) express the genes for critical regu-
lators of Mk and E development strongly support that
LSK Flt3+ cells have undergone an irreversible lineage
commitment step through downregulation of Mk and
E development programs. That the first HSC lineage
restriction step might involve simultaneous loss of Mk
and E potentials is not so surprising in light of Mk and
E lineages sharing a common progenitor, MkEPs
(Akashi et al., 2000), as well as critical regulators of lin-
eage development such as GATA-1 and SCL/TAL-1
(Cantor and Orkin, 2002; Mikkola et al., 2003; Shivda-
sani and Orkin, 1996). In contrast and in agreement with
their sustained G and M potentials, LSK Flt3+ cells
maintained similar expression levels of PU.1 and G-CSFR
as LSK Flt3− HSCs.
Contrary to the current model for hematopoietic de-
velopment (Figure 7A), our findings do not support that
the earliest lineage restriction or commitment event of
adult HSCs results exclusively in a strict separation into
common lymphoid and common myeloid differentiation
pathways. The generation of LSK Flt3+ cells with G, M,B, and T cell, but little or no Mk and E potentials, would
be more compatible with a model in which MkEPs and
LSK Flt3+ cells are primarily generated through asym-
metric cell divisions of LSKCD34+Flt3−/low HSCs (Figure
7B; Yang et al., 2005). A similar model has in fact pre-
viously been proposed based on a hierarchy of tran-
scription factors, with PU.1-deficient HSCs giving rise
to Mk and E progenitors, but not progenitors of the G,
M, B, and T cell lineages (Singh, 1996). Recent studies
of paired daughter cells of purified HSCs also support
that MkEPs might develop from HSCs without a CMP
intermediate (Takano et al., 2004). Furthermore, such a
model is also compatible with the observation of my-
eloid (erythroid- and macrophage-like cells) emerging
earlier in evolution (Hansen and Zapata, 1998) and on-
togeny (Cumano and Godin, 2001) than lymphoid cells.
Alternative and more complex models of HSC lineage
commitment are needed to reconcile the evidence for
CMPs (Akashi et al., 2000; Miyamoto et al., 2002) and
our findings of LSK Flt3+ lymphoid-primed multipotent
progenitors (LMPPs). In one such model, LSKCD34+
Flt3−/low ST-HSCs could upon asymmetrical cell divi-
sions give rise to CMPs and LMPPs (Figure 7C). Impor-
tantly, our studies support the existence of myeloid-
restricted CMPs with a combined MkE and GM poten-
tial (Akashi et al., 2000). However, when compared to
LSK Flt3−, cells very few Flt3− CMPs were found to give
rise to mixed MkE and GM colonies, and in agreement
with recent studies (Nutt et al., 2005), the Lin−IL-
7Rα−Sca-1−c-kit+CD34+FcR−Flt3− candidate CMP pop-
ulation gave rise to primarily pure GM or MkE colonies.
Thus, although Flt3− CMPs represent one pathway for
generation of Mk, E, and GM progenitors, it might not
represent an obligate or even dominating intermediate
for myeloid development from HSCs. Rather than a
strict hierarchical model, our findings might be equally
compatible with a commitment process occurring on a
probabilistic or stochastic basis (Nakahata et al., 1982;
Siminovitch et al., 1963) in which the probability of dif-
ferent commitment fates can be altered by intrinsic and
extrinsic cues, differentially expressed within the LSK
HSC hierarchy. If so, LSKFlt3+/high cells might poten-
tially possess some residual MkE potential, although
our findings of little or no MkE development in the uti-
lized assays, would suggest that such a potential must
be very restricted.
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302Figure 7. Current and Alternative Models for Hematopoietic Stem Cell and Blood Lineage Commitment
(A) Current model (Reya et al., 2001) for hematopoietic lineage commitment and development, postulating that the first lineage commitment
step of HSCs results in a strict separation of myleopoiesis and lymphopoiesis as supported through the identification of CMPs and CLPs,
respectively (Akashi et al., 2000; Kondo et al., 1997).
(B) Alternative model, based on the present studies, in which a pluripotent HSC upon loss of Mk and E potential develops into a lymphoid
primed multipotent progenitor (LMPP) that upon loss of GM potential generates the CLP (Adolfsson et al., 2001).
(C) Composite model, incorporating the experimental evidence for models (A) and (B). Also shown are expression of key genes in ST-HSCs
and LMPPs based on Q-PCR data.
LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-term hematopoietic stem cell; MPP, multipotent progenitor; LMPP, lymphoid-
primed multipotent progenitor; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte/macrophage
pronenitor; MkEP, megakaryocyte/erythroid progenitor; B, B cell; T, T cell.Our findings are particularly intriguing in light of re- d
scent gene profiling studies of HSCs (with full myeloid
and lymphoid lineage differentiation potentials), reveal- s
ping wide expression of myeloid (MkE and GM) but not
lymphoid gene programs (Delassus et al., 1999; Miya- u
bmoto et al., 2002). Combined with our finding, this ob-
servation strongly supports that HSCs might initially be s
eprimed to undergo myeloid (Mk, E, and subsequently
GM) commitment (Figure 7B) and that lymphoid com- o
emitment through an LSK Flt3+ LMPP stage depends on
subsequent activation of lymphoid genes. In that re- s
ggard, it is noteworthy that LSK Flt3+ cells upregulate
gene expression for FLT3 and IL-7Ra, the two cytokine t
areceptors critically involved in lymphoid and B cell
commitment (Peschon et al., 1994; Sitnicka et al., m
e2002). Furthermore, in agreement with their sustained
G and M potential, multiplex single cell PCR analysis s
idemonstrates that IL-7Ra+ LSK Flt3+ cells also sustain
expression of the G-CSFR. i
sIn fetal (but not adult) hematopoiesis, a number of
previous observations have implicated the potential s
rexistence of lympho-myeloid lineage-restricted pro-
genitors, primarily with a combined B cell, monocyte g
m(Cumano et al., 1992; Mebius et al., 2001), and in some
cases also T cell (Lacaud et al., 1998; Lu et al., 2002)
rpotential. However, as emphasized by others (Ema and
Nakauchi, 2003; Katsura, 2002), definitive conclusions F
lhave been difficult to reach based on these studies,
since they have been limited by the fact that the can- bidate progenitors in question have not been pro-
pectively purified and characterized and therefore pre-
ent at low frequencies and assayed along with other
rogenitors showing additional lineage potentials in the
tilized assays. Thus, under such conditions it has not
een possible to conclude whether or not progenitors
howing restricted lineage development are in fact lin-
age restricted or whether it rather reflects the inability
f the utilized assays to efficiently support the full lin-
age potentials of all progenitors investigated. For in-
tance, the granulocyte potential of a multipotent pro-
enitor might go unnoticed if investigated at the wrong
ime or under suboptimal conditions, as granulocytes
re very short lived in vitro, whereas monocytes accu-
ulate with time in such cultures. Thus, to prove the
xistence of other lineage-restricted progenitors, pro-
pective purification must be combined with character-
zation of their lineage potentials in efficient in vitro and
n vivo assays for all lineage potentials, as demon-
trated for LSK Flt3+ cells in the present studies. Pro-
pective purification of such populations will also be
equired to obtain meaningful genetic information re-
arding the genetic determinants of lineage com-
itment.
In conclusion, we have in the adult mouse bone mar-
ow LSK HSC compartment identified a prominent LSK
lt3+ LMPP, which in contrast to true ST- and LT-HSCs
acks significant Mk and E potential but sustains other
lood lineage developmental potentials. This repre-
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303sents the earliest known lineage commitment/restric-
tion step of HSCs, leading us to propose that an alter-
native or complimentary road map to that of the
classical hematopoietic hierarchy must guide adult
blood cell lineage commitment and development. Its
exact identification should greatly facilitate delineation
of the molecular pathways regulating these and other
HSC fate decisions.
Experimental Procedures
Mice
Wild-type C57BL/6(Hbbs) mice were from M&B (Ry, Denmark) and
C57BL/6-Hbbd mice from Jackson Laboratories (Maine). All mice
procedures were performed with consent from the local ethics
committee at Lund University.
Hematopoietic Growth Factors
All cytokines were used at predetermined optimal concentrations,
and all human cytokines utilized have been shown to be fully cross-
reactive with mouse cells. For detailed information on cytokines
see the Supplemental Experimental Procedures.
FACS Purification of Subpopulations of Lin−Sca-1+c-kithi
Bone Marrow Cells and CMPs
All sorts were performed by immunomagnetic-based preenrich-
ment followed by multicolor flow cytometric sorting as previously
described (Adolfsson et al., 2001; Bryder and Jacobsen, 2000).
Briefly, bone marrow cells were incubated in a cocktail of predeter-
mined optimal concentrations of lineage (Lin) antibodies: purified
RA3-6B2 (B220), RB6-8C5 (Gr-1), M1/70 (Mac-1), 53-6.7 (CD8), 53-7
(CD5), H129.19 (CD4), and Ter119, all from PharMingen (San Diego,
California). Lin+ cells were then depleted using sheep anti-rat IgG
(Fc)-conjugated immunomagnetic beads (Dynal, Oslo, Norway).
Lineage-negative/low (Lin−/lo) cells were incubated with CyChrome-
conjugated goat anti-rat antibody (Caltag Laboratories, Bur-
lingame, California) and subsequently stained with FITC-conju-
gated rat anti-mouse E13-161.7 antibody (Sca-1), APC-conjugated
rat anti-mouse 2B8 (c-kit), and PE- or biotin-conjugated rat anti-
mouse Flt3 (A2F10.1) plus streptavidin-PE or isotype-matched con-
trol antibodies (all PharMingen). Cells were also stained with
7-amino actinomycin (7-AAD; Sigma-Aldrich Co., St. Louis, Mis-
souri) to exclude dead cells. To exclude long-term stem cells
(Osawa et al., 1996), Lin−/lo cells were in some experiments stained
with FITC-conjugated rat anti-mouse RAM-34 antibody (CD34),
APC-conjugated rat anti-mouse 2B8 (c-kit), PE-conjugated rat anti-
mouse Flt3 (A2F10.1), and biotin-conjugated E13-161.7 (Sca-1)
plus streptavidin-Tricolor (Caltag). For isolation of Flt3− CMPs
(Akashi et al., 2000; D'Amico and Wu, 2003), Lin− BM cells were
isolated and remaining Lin+ cells visualized as described above.
Cells were subsequently stained with 7-AAD, FITC-conjugated rat
anti-mouse RAM34 (CD34), PE-conjugated rat anti-mouse 2.4G2
(CD16/32; FcγR), Tricolor-conjugated rat anti-mouse D7 (eBio-
sciences, San Diego, California; Sca-1) and Tricolor rat anti-mouse
A7R34 (IL7Rα; eBiosciences), biotin-conjugated rat anti-mouse
A2F10.1 (Flt3) plus streptavidin-PE-Texas-Red (Caltag), or isotype-
matched control antibodies (all PharMingen unless otherwise
indicated). To obtain high purity (reproducibly 97%–99% upon
reanalysis) Lin−/loSca-1+c-kithi(LSK)Flt3+/− and Lin−Sca-1−c-
kit+IL7Rα−FcγRloCD34+Flt3− CMPs were sorted twice on a FACS-
Vantage or FACSDiva Cell Sorter (Becton Dickinson).
Single-Cell Assay for Combined B Cell
and Granulocyte/Macrophage Potential
LSK Flt3+ cells were seeded in Terasaki plates at a concentration
of one cell per well in 20 l serum-free medium (X-vivo15; BioWhit-
taker, Walkersville, Maryland), supplemented with 1% detoxified
Bovine Serum Albumin (StemCell Technologies Inc., Vancouver,
Canada). Cells were cultured in kit ligand (KL) + Flt3 ligand (FL) +
IL-7 for 6 days, at which time proliferating clones were divided, with
one part of the cells continuing in KL + FL + IL-7 for an additional
9 days to establish their B cell potential through evaluation ofB220+CD19+ cells produced in cultures (Veiby et al., 1996). The
other part of the cells were switched to culture conditions promot-
ing GM development (IMDM, BioWhittaker; supplemented with
20% FCS, BioWhittaker), and a cytokine cocktail composed of KL +
FL + IL-3 + thrombopoietin (TPO) + granulocyte colony-stimulating
factor (G-CSF) + granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) for an additional 9 days. GM potential was estab-
lished by transferring individual colonies to slides in a cytospin
centrifuge and examining cells morphologically after May-Gru¨n-
wald/Giemsa-staining.
Clonogenic B and T Cell Assays on OP9 and OP9-Delta
Like1 (OP9-DL1) Cell Lines
OP9 and OP9-DL1 cell lines (kindly provided by Drs. A. Cumano,
Paris, and J.C. Zuniga Pflucker, Toronto) were maintained as de-
scribed (Schmitt and Zuniga-Pflucker, 2002; Vieira and Cumano,
2004) in OptiMEM with L-Glutamine (Invitrogen Corporation, Carls-
bad, California) supplemented with 10% FCS (Gibco Paisley, Scot-
land). Cell lines were trypsinized and prepared at a density of 2 ×
104 cells/ml. Single LSK Flt3+ cells and CMPs were deposited into
wells containing OP9 or OP9-DL1 cell lines (supplemented with FL
50 ng/ml and IL-7 100 ng/ml in OP9 and FL 50 ng/ml in OP-DL1
cocultures and in some experiments with 25 ng/ml KL) by a single
cell depositor unit coupled to a FACSDiva (Becton Dickinson), pro-
viding single cells in >98% of the wells and no wells with more than
1 cell. Clones were identified and picked at days 14, 21, and 28
and analyzed by FACS for presence of B cell (defined as
B220+CD19+) and T cell (defined as CD3+, CD4+, and CD8α+) com-
mitted progeny.
Reverse transcriptase and Polymerase chain reaction analysis of
the clones generated on OP9-DL1 was preformed as described in
the Supplemental Experimental Procedures.
Evaluation of In Vitro Megakaryocyte Potential
of Single LSK Flt3+/− Cells
LSK Flt3+ and LSK Flt3− cells were seeded in Terasaki plates at a
concentration of one cell per well in 20 l serum-free medium (as
above) supplemented with KL + FL + TPO + IL-3 (KFT3) or KL +
IL-3 + erythropoietin (EPO) + IL-11 (K3E11). Wells were scored for
cell growth at different time points. Mk-containing colonies were
identified by light microscopy and confirmed morphologically after
transferring individual colonies to slides in a cytospin centrifuge
and subsequent May-Gru¨nwald/Giemsa-staining.
In Vitro Erythroid Potential Assay
Single LSK Flt3− and LSK Flt3+ cells were seeded in Terasaki plates
in 20 l IMDM supplemented with 1% BIT 9500 (StemCell Technol-
ogies) and KL (50 ng/ml), FL (50 ng/ml), TPO (50 ng/ml), IL-3 (10
ng/ml), and EPO (5 U/ml). After 14–15 days of culture, clones were
picked and stained with PE-conjugated rat anti-mouse TER119 and
APC-conjugated rat anti-mouse Gr-1 (RB6-8C5) and Mac-1 (M1/70)
(all from Becton Dickinson) as well as 7-AAD. Erythroid potential
was defined by the presence of TER119+Gr-1/Mac-1− cells. Cul-
ture-derived TER119+Gr-1/Mac-1− cells were also sorted with a
FACSDiva and subsequently stained with May-Gru¨nwald/Giemsa
to confirm erythroid identity by morphology (data not shown).
In Vitro Combined Myeloid Potentials of CMPs
LSK Flt3− cells and CMPs were deposited as single cells (using a
single cell depositor; see above) into Terasaki plates in 20 l me-
dium (X-vivo15) supplemented with 10% FCS (Gibco) and 0.5%
BSA, 0.1mM β-mercaptoethanol and cytokines, KL + FL + TPO (50
ng/ml each) + IL-3 (10 ng/ml) + EPO (5 U/ml), KL + FL + TPO + G-CSF
(all 50 ng/ml) + IL-3 (10 ng/ml) + EPO (3 U/ml), or KL + FL + TPO +
G-CSF (all 50 ng/ml) + IL-3 (10 ng/ml) + GM-CSF (20 ng/ml) + EPO
(5 U/ml), all giving similar results. After initial optimization of growth
conditions and kinetics, cell growth and multilineage (Mk, E, G, and
M) differentiation (after May-Gru¨nwald/Giemsa staining of clones
containing over 100 cells) were established at day 13–14 for LSK
Flt3− cells and at day 6–7 for CMPs.
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sPotential Assay
Ten thousand LSK Flt3+ or LSK Flt3− cells freshly isolated from H
TC57BL/6 mice (CD45.1) were injected intravenously to lethally irra-
diated (975 cGy) C57BL/6 mice (CD45.2), along with 200,000 un- p
mfractionated congeneic (CD45.2) BM cells providing a competitor
and survival population. Seven to nine days posttransplantation, a
spleen and BM cells were stained with CD45.1, CD45.2, and 7-AAD.
LSK Flt3+/−-derived (CD45.1+CD45.2−7-AAD−) cells were sorted on S
a FACSDiva and evaluated for Mk progenitor potential in serum- T
free methylcellulose (M3226; StemCell Technologies Inc.) supple- t
mented with KL + TPO and for colony forming unit-granylocyte/ g
macrophage (CFU-GM) in FCS containing methylcellulose (M3134; f
StemCell Technologies Inc.) supplemented with KL + TPO + FL +
IL-3 + G-CSF + GM-CSF. GM and Mk colony formation was eval-
uated following 8–12 days of in vitro incubation. S
S
In Vivo Erythroid Potential Assay m
Two hundred FACS-sorted LSK Flt3+ or LSKCD34+Flt3− cells from w
C57BL/6-Hbbs (CD45.1) mice were transplanted into lethally irradi-
ated C57BL/6-Hbbd (CD45.2) mice, along with 200,000 unfraction-
ated congeneic (C57BL/6-Hbbd, CD45.2) BM cells. At 3 and 4 A
weeks after transplantation, peripheral blood (PB) was analyzed for
Hbbs and Hbbd reconstitution (Harrison et al., 1988; Whitney, 1978).
T
Briefly, PB was washed twice with 3 ml PBS (PAA Laboratories
h
GmbH, Linz, Austria). Twenty microliters packed red blood cells
e
were lysed and cystamine modified with 150 l cystamine lyse so-
C
lution for 30 min. The different Hbb isoforms were separated and
a
visualized using a hemoglobin electrophoresis kit (P/N 4411780;
Å
Beckman Coulter Inc., Fullerton, California). Gel-pro analyser version
G
2.0 (Media Cybernetics, Silver Springs, Massachusetts) software was
B
used for quantification of percentage hemoglobin reconstitution. In
each experiment, PB from nontransplanted C57BL/6-Hbbd (CD45.2)
Ö
mice were used as a negative control and PB from nontransplanted
F
C57BL/6-Hbbs (CD45.1) mice as a positive control. The mean back-
2
ground of the electrophoresis assay was 4% (SD = 1%; n = 7).
s
d
Quantitative RT-PCR
LSKCD34+Flt3−/+ cells were FACSDiva sorted directly into 75 l of
Rbuffer-RLT and frozen at −80°C. RNA extraction and DNase treat-
Rment was performed with the RNeasy Micro kit (Qiagen Inc., Cali-
Afornia) according to manufacturers’ instructions for samples con-
Ptaining %105 cells. Eluted RNA samples were reverse transcribed
using SuperScript II and random hexamers (Invitrogen) according
to protocol supplied by the manufacturer. Newly synthesized cDNA R
was diluted to approximately contain cDNA from 30 cells/l and
frozen at −20°C. Q-PCR reactions were performed by mixing 2× A
TaqMan universal PCR master mix, 20× Assays-on-Demand (pri- A
mer/MGB-probe mix), RNase-free H20, and 5l of cDNA for a final (
reaction volume of 25 l. TaqMan Assays-on-Demand probes used L
are described in the Supplemental Experimental Procedures. All l
experiments were performed in triplicates, and differences in cDNA
Ainput were compensated by normalizing against HPRT expression
clevels.
e
BAnalysis of Single Cells by Reverse Transcriptase-Polymerase
pChain Reaction
pMultiplex single-cell RT-PCR analysis of LSK Flt3+ and
CLSKCD34+Flt3− cells was performed according to the methods de-
escribed by Hu et al. (Hu et al., 1997). Single cells were deposited by
3a single-cell depositor coupled to a FACSDiva as described above
(>98% of the wells contained single cells), into 96-well PCR plates C
containing 4 l lysis buffer (0.4% Nonidet P-40, 65 mol/l dNTPs, h
25 mol/l dithiothreitol, and 0.5 U/l RNaseOUT (Invitrogene Cor- l
poration, California). Cell lysates were reverse transcribed using C
multiple (up to 6) pairs of gene-specific reverse primers and 50 U c
MMLV-RT per reaction in the buffer provided by the supplier (Invi- 1
trogene Corporation, California). The first-round PCR with 35 cy-
Ccles was performed by addition of 40 l PCR buffer and 1.25 U Taq
tpolymerase (TaKaRa Bio Inc., Shiga, Japan). One microliter aliquots
Nof first-round PCRs were further amplified using fully nested gene-
specific primers. Aliquots of second-round PCR products were D
dsubjected to gel electrophoresis and visualized by ethidium bro-ide staining on ordinary agarose gels or E-gels (Invitrogene). The
equences for the external and internal oligonucleotide primers for
PRT, CD34, c-kit, and G-CSFR were kindly provided by Professor
ariq Enver, Weatherall Institute, Oxford, England. The external
rimer sequences used are described in the Supplemental Experi-
ental Procedures. Empty wells were used as negative controls
nd never showed any signals for any of the investigated genes.
tatistics
he statistical significance of difference between groups was de-
ermined using the two-tailed paired Student’s t test. For the pro-
enitor data, the Student’s t test was performed after log trans-
ormation of the data.
upplemental Data
upplemental Data include one figure and Supplemental Experi-
ental Procedures and can be found with this article online http://
ww.cell.com/cgi/content/full/121/2/295/DC1/.
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